APRE
Price
$0.91
Change
+$0.01 (+1.11%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
6.31M
Intraday BUY SELL Signals
TBPH
Price
$20.62
Change
+$0.29 (+1.43%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
1.03B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APRE vs TBPH

Header iconAPRE vs TBPH Comparison
Open Charts APRE vs TBPHBanner chart's image
Aprea Therapeutics
Price$0.91
Change+$0.01 (+1.11%)
Volume$707
Capitalization6.31M
Theravance Biopharma
Price$20.62
Change+$0.29 (+1.43%)
Volume$4.71K
Capitalization1.03B
APRE vs TBPH Comparison Chart in %
APRE
Daily Signal:
Gain/Loss:
TBPH
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
APRE vs. TBPH commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APRE is a Hold and TBPH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (APRE: $0.90 vs. TBPH: $20.33)
Brand notoriety: APRE and TBPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APRE: 124% vs. TBPH: 70%
Market capitalization -- APRE: $6.31M vs. TBPH: $1.03B
APRE [@Biotechnology] is valued at $6.31M. TBPH’s [@Biotechnology] market capitalization is $1.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APRE’s FA Score shows that 2 FA rating(s) are green whileTBPH’s FA Score has 0 green FA rating(s).

  • APRE’s FA Score: 2 green, 3 red.
  • TBPH’s FA Score: 0 green, 5 red.
According to our system of comparison, APRE is a better buy in the long-term than TBPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APRE’s TA Score shows that 5 TA indicator(s) are bullish while TBPH’s TA Score has 3 bullish TA indicator(s).

  • APRE’s TA Score: 5 bullish, 3 bearish.
  • TBPH’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, APRE is a better buy in the short-term than TBPH.

Price Growth

APRE (@Biotechnology) experienced а -1.04% price change this week, while TBPH (@Biotechnology) price change was +11.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

TBPH is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TBPH($1.03B) has a higher market cap than APRE($6.31M). TBPH YTD gains are higher at: 8.658 vs. APRE (5.803). TBPH has higher annual earnings (EBITDA): 53.1M vs. APRE (-13.8M). TBPH has more cash in the bank: 330M vs. APRE (13.7M). APRE has less debt than TBPH: APRE (0) vs TBPH (44.6M). TBPH has higher revenues than APRE: TBPH (80.3M) vs APRE (0).
APRETBPHAPRE / TBPH
Capitalization6.31M1.03B1%
EBITDA-13.8M53.1M-26%
Gain YTD5.8038.65867%
P/E RatioN/A35.67-
Revenue080.3M-
Total Cash13.7M330M4%
Total Debt044.6M-
FUNDAMENTALS RATINGS
APRE vs TBPH: Fundamental Ratings
APRE
TBPH
OUTLOOK RATING
1..100
727
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10096
SMR RATING
1..100
9856
PRICE GROWTH RATING
1..100
8837
P/E GROWTH RATING
1..100
485
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APRE's Valuation (14) in the null industry is somewhat better than the same rating for TBPH (79) in the Pharmaceuticals Other industry. This means that APRE’s stock grew somewhat faster than TBPH’s over the last 12 months.

TBPH's Profit vs Risk Rating (96) in the Pharmaceuticals Other industry is in the same range as APRE (100) in the null industry. This means that TBPH’s stock grew similarly to APRE’s over the last 12 months.

TBPH's SMR Rating (56) in the Pharmaceuticals Other industry is somewhat better than the same rating for APRE (98) in the null industry. This means that TBPH’s stock grew somewhat faster than APRE’s over the last 12 months.

TBPH's Price Growth Rating (37) in the Pharmaceuticals Other industry is somewhat better than the same rating for APRE (88) in the null industry. This means that TBPH’s stock grew somewhat faster than APRE’s over the last 12 months.

APRE's P/E Growth Rating (4) in the null industry is significantly better than the same rating for TBPH (85) in the Pharmaceuticals Other industry. This means that APRE’s stock grew significantly faster than TBPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APRETBPH
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 13 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
APRE
Daily Signal:
Gain/Loss:
TBPH
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSCDX31.63N/A
N/A
Fidelity Advisor Small Cap A
RWCIX15.34-0.04
-0.26%
Redwheel Global Emerging Equity I
MSRRX53.77-0.20
-0.37%
MFS Research R2
TINFX26.97-0.16
-0.59%
Thornburg International Growth R5
UGPIX28.46-1.04
-3.53%
ProFunds UltraChina Inv

APRE and

Correlation & Price change

A.I.dvisor tells us that APRE and ATOS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APRE and ATOS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APRE
1D Price
Change %
APRE100%
-1.90%
ATOS - APRE
32%
Poorly correlated
-2.78%
CRBU - APRE
31%
Poorly correlated
+0.63%
TBPH - APRE
30%
Poorly correlated
+3.46%
EYPT - APRE
30%
Poorly correlated
-0.06%
FTRE - APRE
28%
Poorly correlated
-5.60%
More

TBPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, TBPH has been loosely correlated with KYMR. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TBPH jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TBPH
1D Price
Change %
TBPH100%
+3.46%
KYMR - TBPH
40%
Loosely correlated
+1.42%
VYGR - TBPH
40%
Loosely correlated
+3.08%
TARA - TBPH
38%
Loosely correlated
-6.11%
RGNX - TBPH
37%
Loosely correlated
-0.20%
VERA - TBPH
36%
Loosely correlated
+5.68%
More